Immunotherapy: Who Is Eligible?
Immunotherapy: Who Is Eligible?
复制标题
免疫疗法：谁有资格？
DOI：
10.1016/j.otc.2017.04.006
复制
发表时间：
2017
影响因子：
1.7
通讯作者：
Kim,YoungJ
中科院分区：
文献类型：
--
作者：
Wang,Daniel;Gilbert,Jill;Kim,YoungJ
复发性和/或转移性头颈癌预示着传统治疗的预后较差，但目前使用免疫检查点抑制剂的免疫治疗有可能改善这些临床结果。本文主要综述了头颈癌免疫治疗的重大突破，以及该领域未来的发展方向。最终，这种理解将指导临床医生选择头颈癌患者和开始免疫治疗前的实际考虑。
Recurrent and/or metastatic head and neck cancer portends a poor prognosis with traditional treatments, but current immunotherapy with immune checkpoint inhibitors has the potential to improve these clinical outcomes. This review focuses on the major breakthroughs that have led to our current understanding of immunotherapy in head and neck cancer as well as the future direction of the field. Ultimately, this understanding will guide clinicians on the selection of head and neck cancer patients and practical considerations prior to starting immunotherapy.